Last updated: February 12, 2026
Drug Overview:
NDC 72485-0653 is a biosimilar product marketed as Amgen’s Kanjinti (trastuzumab-anns). It is a biosimilar version of Herceptin (trastuzumab), used primarily in HER2-positive breast cancer and metastatic gastric cancer. Its approval spans multiple regions, with accepted biosimilar standards globally.
Market Position:
Kanjinti entered a competitive landscape dominated by Herceptin, which held significant market share prior to biosimilar approvals. The biosimilar landscape in the United States and Europe is mature, with multiple competitors such as Pfizer's Trazimera and Samsung Bioepis's Ontruzant.
Market Size & Trends:
- The global HER2-positive breast cancer market was valued at approximately $9.2 billion in 2022.
- The breast cancer treatment segment grew at a CAGR of 6% from 2017-2022.
- Biosimilars account for an increasing share, projected to reach 55% of trastuzumab sales in North America by 2025.
Market Penetration & Adoption:
- Biosimilar adoption varies by country: in Europe, uptake exceeds 70%; in the US, initial adoption is around 45%, accelerating as patents expire.
- Payers favor biosimilars, offering discounts of 15-25% compared to reference biologics to facilitate substitution.
Pricing Expectations:
- In the US, biosimilars pricing ranges from 15-25% below originator prices. The originator Herceptin has list prices around $70,000 per year per patient.
- Biosimilar prices are expected to stabilize around $55,000-$60,000 per year.
- European prices typically reflect local reimbursement policies, with discounts of 20-30%.
| Price Projection (Next 3-5 Years): |
Year |
Price Range (USD per patient/year) |
Notes |
| 2023 |
$55,000 – $60,000 |
Initial stabilization, high adoption |
| 2024 |
$50,000 – $55,000 |
Increased competition, price pressure |
| 2025 |
$48,000 – $52,000 |
Market saturation, payor negotiations |
Supply & Manufacturing Factors:
- Biosimilar production costs focus on upstream cell culture, downstream purification, and quality assurance.
- Market entry costs are high, but mature manufacturing reduces long-term costs.
Regulatory & Patent Landscape:
- The US patent for Herceptin expired in 2019, enabling biosimilar entry.
- Patent litigation and legal delays affect launch timelines.
- In Europe, biosimilar approval depends on EMA assessments, which have been more generically streamlined.
Competitive Dynamics:
- Other biosimilars are launched, prompting price competition.
- Originator companies respond with loyalty programs and rebates.
- Payor and provider incentives influence switching rates.
Key Risks & Opportunities:
- Patent litigations potentially delay biosimilar market expansion.
- Expansion into emerging markets offers growth prospects but involves price sensitivity.
- Increasing physician and patient acceptance improves market share for biosimilars.
Conclusion:
NDC 72485-0653, marketed as Kanjinti, is positioned in a growing biosimilar segment with expected prices declining gradually over the next five years. The US market will lead in adoption, following a trend of cost containment and increasing biosimilar acceptance worldwide.
Key Takeaways
- Biosimilar pricing will likely average 20% below originator prices within five years.
- Market share growth depends on regional healthcare policies and patent litigations.
- Adoption rates in the US remain below European levels but continue to grow.
- Competition among biosimilars intensifies, exerting downward pressure on prices.
- Long-term growth depends on payor acceptance and potential expansions into new indications.
FAQs
1. When was NDC 72485-0653 approved?
Kanjinti received FDA approval in June 2018 for the treatment of HER2-positive breast cancer and gastric cancer.
2. What are the main competitors for this biosimilar?
Pfizer's Trazimera, Samsung Bioepis's Ontruzant, and other biosimilars like Mylan's Ogivri.
3. What is the current reimbursement environment?
Reimbursement varies; in the US, Medicare and commercial payers increasingly favor biosimilars with negotiated discounts.
4. How does patent litigation affect the market?
Patent disputes can delay biosimilar entry or limit market share growth if patents are challenged successfully.
5. What is the future outlook for prices?
Prices are expected to decline gradually, averaging around $50,000-$55,000 per year per patient within three years, due to increased competition and payer negotiations.
References
[1] IQVIA, "Global Oncology Trends," 2022.
[2] FDA, "Kanjinti (trastuzumab-anns) Approval Letter," 2018.
[3] EvaluatePharma, "Biosimilar Markets," 2022.
[4] European Medicines Agency, "Biosimilars Summary," 2022.
